Ken Griffin Neurocrine Biosciences Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 47,000 shares of NBIX stock, worth $5.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,000

Previous 36,300 29.48%

Holding current value

$5.91 Million

Previous $5 Million 8.28%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $117 Million - $157 Million	1,023,651 Added 138.16%	1,764,590 $203 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $13.1 Million - $14.4 Million	-100,379 Reduced 11.93%	740,939 $102 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $95.1 Million - $105 Million	729,318 Added 651.18%	841,318 $116 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $66.2 Million - $82.9 Million	-624,207 Reduced 84.79%	112,000 $14.8 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $53.6 Million - $66.8 Million	-570,066 Reduced 43.64%	736,207 $82.8 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $74.5 Million - $87.2 Million	831,881 Added 175.36%	1,306,273 $123 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $27.2 Million - $35.5 Million	288,824 Added 155.64%	474,392 $48 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $5.34 Million - $6.36 Million	-50,078 Reduced 21.25%	185,568 $22.2 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $21.7 Million - $25.4 Million	235,646 New	235,646 $25 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $52.9 Million - $69.2 Million	-729,731 Reduced 88.69%	93,098 $8.73 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $1.69 Million - $2.25 Million	-21,172 Reduced 2.51%	822,829 $70.1 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $15.2 Million - $17.4 Million	176,015 Added 26.35%	844,001 $80.9 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $41.8 Million - $47.8 Million	-467,361 Reduced 41.16%	667,986 $65 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $1.06 Million - $1.45 Million	-12,160 Reduced 1.06%	1,135,347 $110 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $72.7 Million - $90.6 Million	836,009 Added 268.38%	1,147,507 $110 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $16.1 Million - $22.6 Million	167,143 Added 115.79%	311,498 $30 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $72.6 Million - $111 Million	-852,854 Reduced 85.52%	144,355 $17.6 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $43 Million - $65.2 Million	573,054 Added 135.1%	997,209 $86.3 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $21.2 Million - $28.9 Million	243,978 Added 135.41%	424,155 $45.6 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $10.4 Million - $12.6 Million	124,617 Added 224.29%	180,177 $16.2 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $344,584 - $435,357	4,770 Added 9.39%	55,560 $4.69 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $26.9 Million - $35.6 Million	-388,808 Reduced 88.45%	50,790 $0
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $2.32 Million - $2.95 Million	23,431 Added 5.63%	439,598 $0
Q2 2018 Aug 10, 2018	BUY	$75.3 - $105.99 $7.38 Million - $10.4 Million	97,981 Added 30.79%	416,167 $0
Q1 2018 May 11, 2018	SELL	$75.88 - $92.43 $16.6 Million - $20.3 Million	-219,221 Reduced 40.79%	318,186 $26.4 Million
Q4 2017 Feb 09, 2018	BUY	$58.53 - $77.59 $18.8 Million - $24.9 Million	320,800 Added 148.1%	537,407 $41.7 Million
Q3 2017 Nov 09, 2017	BUY	$47.97 - $61.28 $10.4 Million - $13.3 Million	216,607	216,607 $13.3 Million

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account